This healthcare franchise combines a perfect four-quarter earnings beat streak averaging 23.2% positive surprise, 63% revenue growth, a maximum Piotroski financial health score, and a golden-cross technical breakout — one of the highest-quality growth setups in the universe — though the 5.1% upside at the current spot price creates an asymmetry gap that favors waiting for a pullback near the $812.92 entry target.
Thesis pillars
- Exceptional Business Quality→Stable
- Perfect Four Quarter Beat Streak↓Deteriorating
- Sixty Three Percent Revenue Growth→Stable
- +2 more pillars — see the Why tab for full reasoning
argenx SE (ARGX) Stock Analysis
Temporary headwind edge
Healthcare · Biotechnology
Wait — supporting gate not met yet. Price is at or below entry $960.36 but weak momentum still blocks BUY_NOW. Key risk: Negative momentum.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP),... Read more
Wait — supporting gate not met yet. Price is at or below entry $960.36 but weak momentum still blocks BUY_NOW. Key risk: Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.15, quality 8.1/10, growth 10.0/10). Score 7.0/10, high confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 27d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: speculative.
Recent developments
updated 2026-09-26Recent Developments — argenx SE
Latest news
- NEWS Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - Yahoo Finance — Yahoo Finance neutral
- NEWS Is Argenx (ARGX) Outperforming Other Medical Stocks This Year? - finance.yahoo.com — finance.yahoo.com positive
- NEWS ARGX|argenx SE|Price:861.810|Chg%:-20.750 - TradingKey — TradingKey negative
- NEWS argenx SE (ARGX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey — TradingKey neutral
- NEWS TD Cowen Maintains Argenx SE(ARGX.US) With Buy Rating, Maintains Target Price $1,146 - Moomoo — Moomoo positive
Generated 2026-09-26T10:02:21Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Wait — supporting gate not met yet. Price is at or below entry $960.36 but weak momentum still blocks BUY_NOW. Key risk: Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.15, quality 8.1/10, growth 10.0/10). Target $1062.55 (+10.7%), stop $916.99 (−4.6%), A.R:R 2.1:1. Score 7.0/10, high confidence.
Take-profit target: $1062.55 (+10.7% upside). Target $1062.55 (+10.7%), stop $916.99 (−4.6%), A.R:R 2.1:1. Stop-loss: $916.99.
Negative momentum.
argenx SE trades at a P/E of 36.0 (forward 27.7). TrendMatrix value score: 4.6/10. Verdict: Buy (Wait for Entry).
25 analysts cover ARGX with a consensus score of 4.2/5. Average price target: $1181.
What does argenx SE do?argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in...
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.